ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mazdutide

Also written as “IBI362”, “LY3305677” and “Mazdutide”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight · Fatty Liver · Alcoholism, led by 2 companies.

Drug pageMazdutide: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 19, 202227 company-led studies, 9 open or runningLicense: Lilly → Innovent, Aug 2019Next primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics208 open or runningphase 3since Oct 19, 2022Jun 5, 2020Dec 31, 2026phase 3 · NCT06884293
Eli Lillyits history only71 open or runningphase 2since Nov 6, 2023Nov 21, 2016Sep 2027phase 2 · NCT06143956

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Innovent Biologics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 3 earlier studies, Jun 5, 2020 to Feb 21, 2021.

  1. Aug 21, 2019Innovent licensed it from LillyLicenseChina · announced · Innovent (release)
  2. May 25, 2021Phase 2 study in Overweight/ ObesityNCT04904913 · 328 enrolled · China
  3. Jul 15, 2021Phase 2 study in Diabetes Mellitus, Type 2NCT04965506 · 252 enrolled · China
  4. Jan 25, 2022Named mazdutideINNProposed as its International Nonproprietary Name in WHO's List 126 · before, IBI362, LY3305677
  5. Oct 19, 20222 phase 3 studiesNCT05606913, NCT05607680
  6. Nov 17, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05628311 · 319 enrolled · China
  7. Mar 20, 20232 phase 1 studiesNCT05815680, NCT05793450
  8. Dec 1, 20232 phase 3 studiesNCT06164873, NCT06184568
  9. Jul 25, 2024Phase 1 study in Adolescents With ObesityNCT06536023 · 36 enrolled · China
  10. Feb 19, 2025Phase 2 study in ObesityNCT06862908 · 141 enrolled · China
  11. Mar 11, 2025Phase 3 study in OverweightNCT06884293 · 479 enrolled · China
  12. Apr 7, 2025Phase 2 study in Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT06937749 · 181 enrolled · China
  13. Apr 9, 2025Phase 3 study in Sleep Apnea SyndromesNCT06931028 · 260 planned · China
  14. May 8, 2025Phase 2 study in ObesityNCT07000955 · 98 enrolled · China
  15. Nov 19, 2025Phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesNCT07255209 · 180 planned · China
  16. Feb 27, 2026Phase 3 study in OverweightNCT07469800 · 336 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in OverweightNCT06884293
  2. May 7, 2027Primary completion: phase 3 study in Sleep Apnea SyndromesNCT06931028
  3. Oct 31, 2027Primary completion: phase 3 study in Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesNCT07255209

TargetBeta

GLP1R →read by rule
“Mazdutide is a synthetic peptide analog of mammalian oxyntomodulin and a once-weekly dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), under development for the treatment of obesity and type 2 diabetes (T2D).”study text, by rule · the study

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 20 Innovent Biologics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07469800Overweight · China3RecruitingAug 1, 2026336
NCT07255209Adolescents With Obesity or Overweight With Weight-Related Comorbidities · China3RecruitingOct 31, 2027180
NCT07000955Obesity · China2Active, not recruitingSep 30, 202698
NCT06931028Sleep Apnea Syndromes · China3RecruitingMay 7, 2027260
NCT06937749Metabolic Dysfunction-associated Steatohepatitis (MASH) · China2Active, not recruitingSep 23, 2026181
NCT06884293Overweight · China3Active, not recruitingDec 31, 2026479
NCT06862908Obesity · China2Active, not recruitingSep 24, 2026141
NCT06536023Adolescents With Obesity · China1CompletedJul 22, 202536
NCT06184568Diabetes Mellitus, Type 2 · China3CompletedSep 17, 2025349
NCT06164873Obesity · China3Active, not recruitingJun 27, 2025462
NCT05815680Overweight Subjects · China1CompletedAug 18, 202348
NCT05793450Renal Insufficiency · China1CompletedSep 18, 202320
NCT05628311Diabetes Mellitus, Type 2 · China3CompletedOct 25, 2023319
NCT05607680Obesity Or Overweight · China3CompletedAug 21, 2023610
NCT05606913Diabetes Mellitus, Type 2 · China3CompletedJan 26, 2024731
NCT04965506Diabetes Mellitus, Type 2 · China2CompletedApr 28, 2022252
NCT04904913Overweight/ Obesity · China2CompletedMar 29, 2023328
NCT04773977Overweight · China1CompletedMar 9, 202124
NCT04466904Diabetes Mellitus, Type 2 · China2CompletedMay 28, 202142
NCT04440345Overweight · China2CompletedJun 16, 202160

How it is read

Names in the registry

  • “IBI362”, 19 entries
  • “LY3305677”, 5 entries
  • “Mazdutide”, 2 entries
  • “IBI362 liquid formulation”, 1 entry
  • “IBI362 lyophilized powder”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.